TCIM
MYGN icon

TIAA CREF Investment Management’s Myriad Genetics MYGN Stock Holding History

TIAA CREF Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$4.43M Sell
133,382
-23,681
-15% -$721K ﹤0.01% 1529
2018
Q4 		$4.57M Buy
157,063
+21,962
+16% +$790K ﹤0.01% 1444
2018
Q3 		$6.21M Sell
135,101
-11,399
-8% -$507K ﹤0.01% 1422
2018
Q2 		$5.47M Sell
146,500
-11,950
-8% -$404K ﹤0.01% 1534
2018
Q1 		$4.68M Sell
158,450
-1,938
-1% -$65.6K ﹤0.01% 1593
2017
Q4 		$5.51M Sell
160,388
-9,589
-6% -$323K ﹤0.01% 1548
2017
Q3 		$6.15M Sell
169,977
-4,547
-3% -$130K ﹤0.01% 1488
2017
Q2 		$4.51M Sell
174,524
-10,690
-6% -$227K ﹤0.01% 1666
2017
Q1 		$3.56M Sell
185,214
-11,698
-6% -$207K ﹤0.01% 1796
2016
Q4 		$3.28M Sell
196,912
-19,330
-9% -$350K ﹤0.01% 1900
2016
Q3 		$4.45K Sell
216,242
-63
-0% -$1.6K ﹤0.01% 1682
2016
Q2 		$6.62M Sell
216,305
-2,387
-1% -$82.9K 0.01% 1342
2016
Q1 		$8.19M Sell
218,692
-6,186
-3% -$233K 0.01% 1172
2015
Q4 		$9.71M Sell
224,878
-5,328
-2% -$225K 0.01% 1088
2015
Q3 		$8.63M Buy
230,206
+42,240
+22% +$1.5M 0.01% 1143
2015
Q2 		$6.39M Sell
187,966
-14,758
-7% -$502K ﹤0.01% 1494
2015
Q1 		$7.18M Sell
202,724
-320,183
-61% -$11.5M 0.01% 1375
2014
Q4 		$17.8M Sell
522,907
-153,155
-23% -$5.43M 0.01% 820
2014
Q3 		$26.1M Sell
676,062
-226,349
-25% -$8.45M 0.02% 677
2014
Q2 		$35.1M Buy
902,411
+753,223
+505% +$28M 0.02% 599
2014
Q1 		$5.1M Sell
149,188
-145,423
-49% -$4.51M ﹤0.01% 1596
2013
Q4 		$6.18M Buy
294,611
+71,354
+32% +$1.8M ﹤0.01% 1476
2013
Q3 		$5.25M Buy
223,257
+11,961
+6% +$340K ﹤0.01% 1551
2013
Q2 		$5.68M Buy
+211,296
New +$6.12M ﹤0.01% 1432

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TIAA CREF Investment Management's MYGN Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Myriad Genetics (MYGN) stake by 15% in Q1 2019, selling an estimated $721K and leaving 133,382 shares worth $4.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1529.

TIAA CREF Investment Management first reported a position in MYGN in Q2 2013 and has held it in 24 quarters since. The position peaked at $35.1M in Q2 2014. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

  • TIAA CREF Investment Management held 133,382 shares of Myriad Genetics worth $4.43M as of Q1 2019.
  • TIAA CREF Investment Management sold 23,681 Myriad Genetics shares in Q1 2019, an estimated $721K.
  • Myriad Genetics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1529 holding.
  • TIAA CREF Investment Management first reported a position in Myriad Genetics in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Myriad Genetics position peaked at $35.1M in Q2 2014.
  • 262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.